2-甲氧基-5-甲基-3-硝基砒啶 | 33252-62-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-甲氧基-5-甲基-3-硝基砒啶
• 中文别名: 2-甲氧基-5-甲基-3-硝基吡啶
• 英文名称: 2-methoxy-5-methyl-3-nitropyridine
• CAS: 33252-62-9
• 化学式: C₇H₈N₂O₃
• mdl: MFCD09258778
• 分子量: 168.152
• InChiKey: QCQICELALGZQRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methoxy-5-methyl-3-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methoxy-5-methyl-3-nitropyridine
CAS number: 33252-62-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8N2O3
Molecular weight: 168.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲氧基-5-甲基-3-硝基砒啶 在 哌啶 、 N-溴代丁二酰亚胺(NBS) 、 水 、 双氧水 、 铁粉 、 sodium carbonate 、 potassium carbonate 、 溶剂黄146 、 苯甲酸 、 sodium hydroxide 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 66.0h， 生成 (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)amino)acetic acid
  参考文献：
  名称：

  （E）-3-（（苯乙烯基磺酰基）甲基）吡啶和（E）-2-（（苯乙烯基磺酰基）甲基）吡啶衍生物作为抗癌剂的发现：合成，结构-活性关系和生物活性

  摘要：

  ON01910.Na是一种高效的抗癌剂，可诱导有丝分裂阻滞和细胞凋亡。ON01910在癌症患者中的临床研究显示出疗效以及令人印象深刻的安全性。尽管ON01910对癌细胞具有高活性，但口服利用率低，需要连续静脉输注或多克剂量才能确保患者充分的药物暴露以实现其生物学活性。我们已经确定了两个新颖的苯乙烯基磺酰基-甲基吡啶系列。铅化合物8，图9A，18和19A是高度有效的有丝分裂抑制剂和选择性的细胞毒性，以癌细胞。令人印象深刻的是，这些化合物具有出色的药物特性和两个候选候选药物9a还有18个在动物模型中证明了抗肿瘤活性。

  DOI：

  10.1021/jm4019614
• 作为产物：
  描述：

  2-羟基-5-甲基-3-硝基吡啶 在 吡啶 、 sodium 、 三氯氧磷 作用下， 以 氯苯 为溶剂， 反应 5.0h， 生成 2-甲氧基-5-甲基-3-硝基砒啶
  参考文献：
  名称：

  （E）-3-（（苯乙烯基磺酰基）甲基）吡啶和（E）-2-（（苯乙烯基磺酰基）甲基）吡啶衍生物作为抗癌剂的发现：合成，结构-活性关系和生物活性

  摘要：

  ON01910.Na是一种高效的抗癌剂，可诱导有丝分裂阻滞和细胞凋亡。ON01910在癌症患者中的临床研究显示出疗效以及令人印象深刻的安全性。尽管ON01910对癌细胞具有高活性，但口服利用率低，需要连续静脉输注或多克剂量才能确保患者充分的药物暴露以实现其生物学活性。我们已经确定了两个新颖的苯乙烯基磺酰基-甲基吡啶系列。铅化合物8，图9A，18和19A是高度有效的有丝分裂抑制剂和选择性的细胞毒性，以癌细胞。令人印象深刻的是，这些化合物具有出色的药物特性和两个候选候选药物9a还有18个在动物模型中证明了抗肿瘤活性。

  DOI：

  10.1021/jm4019614

文献信息

• Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases
  作者：Jordi Bach、Paul Eastwood、Jacob González、Elena Gómez、Juan Antonio Alonso、Silvia Fonquerna、Estrella Lozoya、Adela Orellana、Mónica Maldonado、Elena Calaf、Joan Albertí、Juan Pérez、Ana Andrés、Neus Prats、Cristina Carreño、Elena Calama、Jorge De Alba、Marta Calbet、Montserrat Miralpeix、Isabel Ramis

  DOI：10.1021/acs.jmedchem.9b00533

  日期：2019.10.24

  in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure–activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced

  Janus激酶（JAKs）在调节与哮喘和慢性阻塞性肺疾病有关的炎性细胞因子的表达和功能中起关键作用。本文描述了一系列适合吸入给药的新型嘌呤酮JAK抑制剂的设计，合成和药理学评估。用吡啶酮环代替该系列起始化合物中存在的咪唑并吡啶铰链结合基序可减轻细胞的细胞毒性。由结构生物学研究推动的进一步的系统构效关系（SAR）的努力导致发现了吡啶酮34，一种有效的泛JAK抑制剂，具有良好的选择性，较长的肺保留时间，较低的口服生物利用度，并且在通过吸入途径经脂多糖诱导的气道炎症大鼠模型中被证明具有疗效。
• [EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
  申请人：FRONTHERA U S PHARMACEUTICALS LLC

  公开号：WO2020185755A1

  公开（公告）日：2020-09-17

  Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

  本发明描述了用于治疗TYK2介导的疾病的化合物。在某些实施方式中，TYK2介导的疾病是一种自身免疫性疾病、炎症性疾病、增殖性疾病、内分泌疾病、神经疾病或与移植相关的疾病。
• [EN] COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS
  申请人：UNIV NOTTINGHAM

  公开号：WO2011161446A1

  公开（公告）日：2011-12-29

  .A compound of formula (I) or a pharmaceutically acceptable salt or solvate or physiologically hydrolysable, solubilising or immobilisable derivative thereof; wherein: any one or two of X·,, X2 and X3 is a N atom and the remaining two or one of X1, X2 and X3 are independently CR13; Y is selected from S02 and SO; R1, R2, R3, and R7 and the one or two R13 groups are each independently selected from H and R10, R10 is selected from R8, alkyl, aryl, heteroaryl and combinations of two or more thereof and combinations with one or more R9, or R10 is one or more moieties R11 Sinking one or more alkyl, alkoxy, aryl, heteroaryl or R8 or R9 groups or combinations thereof, directly or via a moiety selected from alkylene, arylene, heteroarylene or combinations thereof, wherein alkyl, aryl, heteroaryl groups or moieties thereof may be substituted with one or more groups R12, or R10 is selected from a group R12; R11 is selected from 0-, N-, NH-, N=C, CO-, C00-, CON-, CONH-, S02-, S02N-, S02NH-; R12 is selected from halogeno, NH2, N02, CN, OH, COOH, CONH2, C(=NH)NH2, S03H, S02NH2, S02CH3, OCH3, OCH2CH3, CF3; R8 and R9 comprise one or more solubilising moieties independently chosen from i) neutral hydrophilic groups, ii) ionisable organic acids, iii) ionisable organic bases, iv} chemical functions or moieties providing covalent or non-covalent attachment or binding to a solid phase or an immobile receptor and combinations thereof; R4, R5 and R6 are each independently selected from H and R10, or two of R4 to R6 are linked to form a cyclic ether or amine containing one or more additional oxygen or nitrogen atoms. The compound may be used for treating a condition mediated by one or more enzymes selected from AKT, Aurora kinase, BCR-ABL, CDK, FLT, GSK3, IKK, JAK, MAPK, PDGF, PI3K, PKA, PKB, PKC, PLK, Src and VEGF family enzymes, or for treating cancer or other proliferative disorder, or for inhibiting growth of cancer cells, or for inducing apoptosis of cancer cells, in a human or animal subject.

  化合物的化学式（I）或其药学上可接受的盐、溶剂或生理可水解、溶解或固定衍生物；其中：X1、X2和X3中的任意一个或两个是N原子，其余的X1、X2和X3中的一个或两个是独立的CR13；Y从S02和SO中选择；R1、R2、R3和R7以及一个或两个R13基团分别独立选择自H和R10，R10从R8、烷基、芳基、杂环芳基及两种或两种以上的组合以及与一个或多个R9的组合中选择，或R10是一个或多个基团R11，其中沉积一个或多个烷基、烷氧基、芳基、杂环芳基或R8或R9基团或其组合，直接或通过从烷基、芳基、杂环芳基或其组合中选择的基团，其中烷基、芳基、杂环芳基基团或其基团可能被一个或多个基团R12取代，或R10从基团R12中选择；R11从0-、N-、NH-、N=C、CO-、COO-、CON-、CONH-、S02-、S02N-、S02NH-中选择；R12从卤素、NH2、N02、CN、OH、COOH、CONH2、C(=NH)NH2、S03H、S02NH2、S02CH3、OCH3、OCH2CH3、CF3中选择；R8和R9包括一个或多个独立选择的溶解基团，从i）中性亲水基团，ii）可离子化的有机酸，iii）可离子化的有机碱，iv）提供共价或非共价附着或结合到固相或不动的受体的化学功能或基团或其组合中选择；R4、R5和R6分别独立选择自H和R10，或R4到R6中的两个被连接形成含有一个或多个额外氧或氮原子的环醚或胺。该化合物可用于治疗由AKT、Aurora激酶、BCR-ABL、CDK、FLT、GSK3、IKK、JAK、MAPK、PDGF、PI3K、PKA、PKB、PKC、PLK、Src和VEGF家族酶中选择的一个或多个酶介导的疾病，或用于治疗癌症或其他增生性疾病，或用于抑制癌细胞的生长，或用于诱导人类或动物主体中癌细胞的凋亡。
• [EN] PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE PYRIDIN-2(1H)-ONE UTILES EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE TROUBLES MYÉLOPROLIFÉRATIFS, DU REJET DE GREFFE, DE MALADIES À MÉDIATION IMMUNITAIRE ET INFLAMMATOIRES
  申请人：ALMIRALL SA

  公开号：WO2012160030A1

  公开（公告）日：2012-11-29

  Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  揭示了具有化学结构的化合物（I）的公式；以及它们的制备过程，包括它们的药物组合物和它们作为Janus激酶（JAK）抑制剂在治疗中的用途。
• PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES
  申请人：Eastwood Paul Robert

  公开号：US20140170110A1

  公开（公告）日：2014-06-19

  Compounds having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  公开了具有化学式（I）的化合物；以及它们的制备方法、包含它们的制药组合物以及它们作为Janus激酶（JAK）抑制剂在治疗中的用途。